Skip to main content

Committee To Evaluate Drugs

Ministry
Health
URL
www.health.gov.on.ca/english/providers/program/drugs/how_drugs_approv/funding_ced.html
Address
C/O DRUG PROGRAMS BRANCH, 3RD FLOOR, 5700 YONGE STREET
NORTH YORK
M2M4K5
Phone
(416) 327-8109;
Fax
(416) 327-8123
Background
Ministry of Health and Long-Term Care Act, R.S.O. 1990, c. M.26, s. 9; OC 2217/68; OC 3478/72; OC 2731/94; OC 691/97; OC 2069/98; OC 1250/99; OC 1873/2006; OC 1393/2007 (opens a new window)
Function

The Committee to Evaluate Drugs (CED) (formerly known as the Drug Quality and Therapeutics Committee) was established in 1968 to provide independent and specialized advice to the Ministry, including the Executive Officer of the Ontario Public Drug Programs, on drug-related issues. The CED performs an advisory role for the Ministry on the operations of programs designed to assist the people of Ontario to obtain prescribed pharmaceutical products of quality at reasonable cost. Its key functions are to evaluate the quality, therapeutic value and cost of drug products and to recommend to the Executive Officer, those products which should be considered for publicly funded drug programs, and the conditions under which such products should be funded. The CED also recommends to the Executive Officer which drug products should be designated as interchangeable products or listed drug products for the purposes of the Drug Interchangeability and Dispensing Fee Act and the Ontario Drug Benefit Act  and to monitor and evaluate, on a continuous basis, the list of drugs available in light of drug use patterns, experience and current scientific knowledge. The CED also makes recommendations, when requested, to contribute to and support Ministry efforts on education about publicly funded drugs and related issues. In addition, the CED acts as liaison between the Minister or Executive Officer and professional, educational and other groups. It provides advice on relevant drug, pharmaceutical, policy, and therapeutic questions and issues solicited or requested by the Ministry.

Membership

The Lieutenant Governor in Council appoints not more than sixteen members plus the chair of which two members are lay persons/patient members. The Director of the Drug Programs Policy and Strategy Branch is designated as the Executive Secretary and the Senior Manager, Drug Benefits Management unit of the Drug Programs Policy and Strategy Branch is designated as the Senior Consultant.

Term

Members are appointed for a term of up to three years and may be renewed at the recommendation of the Minister.

Meetings
The committee meets bimonthly to carry out its mandate with respect to drug product reviews, formulary review, and Ontario Drug Benefit program cost-saving initiatives.
Remuneration

Appointees to the Committee to Evaluate Drugs are remunerated on a per diem basis as follows: Chair: $1,200; Professional member: $1,000; Lay person/patient member: $355

Appointments & Vacancies

No. Position Member Term Location
1. Member (Part-Time) EYAL COHEN
12-Dec-2019 - 11-Dec-2022
toronto
2. Member (Part-Time) MAUREEN SMITH
07-Jan-2021 - 06-Jan-2023
ottawa
3. Member (Part-Time) KELVIN CHAN
24-Apr-2020 - 23-Apr-2023
richmond hill
4. Member (Part-Time) BARBARA MOORE
16-Sep-2021 - 15-Sep-2024
hamilton